ID   A549-R0
AC   CVCL_A1ZX
DR   cancercelllines; CVCL_A1ZX
DR   Wikidata; Q105506038
RX   PubMed=8132585;
CC   Group: Serum/protein free medium cell line.
CC   Population: Caucasian.
CC   Doubling time: 8-10 days (PubMed=8132585).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0023 ! A-549
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=8132585; DOI=10.1016/S0021-9258(17)37236-8;
RA   Siegfried J.M., Han Y.-H., DeMichele M.A.A., Hunt J.D., Gaither A.L.,
RA   Cuttitta F.;
RT   "Production of gastrin-releasing peptide by a non-small cell lung
RT   carcinoma cell line adapted to serum-free and growth factor-free
RT   conditions.";
RL   J. Biol. Chem. 269:8596-8603(1994).
//